KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBT Margin (2016 - 2025)

Jazz Pharmaceuticals has reported EBT Margin over the past 16 years, most recently at 17.4% for Q4 2025.

  • For Q4 2025, EBT Margin rose 516.0% year-over-year to 17.4%; the TTM value through Dec 2025 reached 8.63%, down 2019.0%, while the annual FY2025 figure was 14.71%, 2627.0% down from the prior year.
  • EBT Margin for Q4 2025 was 17.4% at Jazz Pharmaceuticals, up from 0.8% in the prior quarter.
  • Over five years, EBT Margin peaked at 22.33% in Q1 2021 and troughed at 70.34% in Q2 2025.
  • A 5-year average of 1.25% and a median of 2.25% in 2022 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: surged 6147bps in 2021 and later crashed -8381bps in 2025.
  • Year by year, EBT Margin stood at 5.0% in 2021, then crashed by -600bps to 34.97% in 2022, then skyrocketed by 117bps to 6.08% in 2023, then soared by 101bps to 12.24% in 2024, then surged by 42bps to 17.4% in 2025.
  • Business Quant data shows EBT Margin for JAZZ at 17.4% in Q4 2025, 0.8% in Q3 2025, and 70.34% in Q2 2025.